:

;
.


&

 (2006-2012)

2006

2012

38 (4.1)

11 (1.1)

0.005

597 (63.6)

573 (56.4)

0.001

303 (32.3)

431 (42.5)

0.001

627 (66.8)

813 (80.4)

< 0.001

416 (44.3)

268 (26.6)

< 0.001

73 (7.8)

22 (2.2)

< 0.001

118 (12.5)

27 (2.7)

< 0.001

159 (17.0)

50 (4.9)

< 0.001

351 (34.5)

39 (3.8)

*
*
*
TZD*

DPP-IV*

GLP-1*

, 13 , 2013


(GLP-1 > DPP-IV)
(DPP-IV) (GLP-1)

(-GLP-1 )

2013:

Diabetes Care 2013 May e-pub ahead of print

Michael Nauck:
.
Peter Buttler, Edwin Gale, Michael Elashoff, Robert Elashoff:
.


2005-2013:

2006-2007:

Diabetes Care 2006: 471

FDA Alert 10/2007

FDA has reviewed 30 postmarketing reports of acute
pancreatitis

SPC -GLP-1 DPP-IV

2009:

Diabetes 2009: 1604

 Ca

GLP-1

GLP-1R ,

GLP-1

Endocrinology 2004: 2653, J Hist Cyt 2008:841


Ca
GLP-1

PDGs

PanIN [GLP-1R +]




( 60 )
2

, ,

Diabetes 2012: 1250


HIP ( )

[ ]

Diabetes 2009: 1604


(1)

Diabetes 2009: 1604


(2)

Diabetes 2009: 1604


Kras ( Ca )
(in vitro)
Exendin-4 12

(PanIN)
GLP-1 PanIN

Diabetes 2012: 1243


ZDF

( FDA)
13 ( 250 g/kg
1.0mg/Kg )

Diabetes Obes Metab 2013:417

Am J Physiol Endocr Metab 2012:E253

(ZDF)

>1

(HIP, Kras)

- Underpowered

Int J Clin Pract 2010: 984

 FDA

/

(FDA, MEA)

Elashoff et al., Gastroenterology 2011


( )

Nauck M, Diabetes Care, May 2013


(2)

> 30

1264
OR: 2.01 [1.19-3.38]

JAMA Intern Med 2013: 2720

:


14
12
( 1;;;)
8
1 (7 , 1 )
Butler et al. Diabetes 2013

Butler et al. Diabetes 2013

( PanIN)
-, 3/8
()
:
(ALS)

Veld et al, Diabetes 2010

case reports
( )

( )

(underpowered)
RR
;;;

(peer reviewed case report)

-

,
.

(n=8)
- -


;

SPC
( )

(2015-2018)